	US 11,753,469 B2
	Methods of using bispecific CD33 and CD3 binding proteins
Luke Evnin, San Francisco, CA (US); Jeanmarie Dean Guenot, San Francisco, CA (US); and Lori Kunkel, San Francisco, CA (US)
Assigned to Anji Bruno, LLC, Cambridge, MA (US)
Filed by Anji Bruno, LLC, Cambridge, MA (US)
Filed on Aug. 10, 2020, as Appl. No. 16/989,671.
Application 16/989,671 is a continuation of application No. 15/578,185, granted, now 10,738,118, previously published as PCT/US2016/034479, filed on May 26, 2016.
Claims priority of provisional application 62/266,438, filed on Dec. 11, 2015.
Claims priority of provisional application 62/168,641, filed on May 29, 2015.
Prior Publication US 2021/0032339 A1, Feb. 4, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/00 (2006.01); C07K 16/28 (2006.01); A61P 35/02 (2006.01); A61K 51/10 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/2809 (2013.01) [A61K 51/10 (2013.01); A61P 35/02 (2018.01); C07K 16/2803 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/622 (2013.01); C07K 2317/626 (2013.01); C07K 2317/73 (2013.01); C07K 2317/92 (2013.01)]

22 Claims

1. A method for the treatment of acute myelogenous leukemia (AML) in a patient having received hematopoietic stem cell transplantation comprising administering a therapeutically effective amount of a homodimeric protein that binds to human CD33 and human CD3, wherein the protein comprises a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 134, 136 and 138.